目的 研究苦碟子注射液聯(lián)合依達拉奉注射液治療急性腦梗死的臨床療效。方法 選擇2014年1月—2017年12月楊凌示范區(qū)醫(yī)院的急性腦梗死患者71例作為研究對象，按治療方法將患者分為對照組35例和觀察組36例。對照組靜脈滴注依達拉奉注射液，30 mg/次，2次/d；觀察組在對照組的基礎上靜脈滴注苦碟子注射液，40 mL/次，1次/d。兩組均持續(xù)治療2周。觀察兩組患者的臨床治療效果，比較兩組患者治療前后日常生活活動能力（ADL）量表評分、美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、血清白介素-6、腫瘤壞死因子-α、白介素-23水平的變化。結果 治療后，觀察組的治療有效率為91.67%，明顯高于對照組的71.43%，差異具有統(tǒng)計學意義（P<0.05）。兩組治療后的ADL量表評分均明顯升高，NIHSS量表評分明顯降低（P<0.05），且觀察組ADL量表和NIHSS量表評分均顯著優(yōu)于對照組（P<0.05）。兩組治療后的白介素-6、腫瘤壞死因子-α和白介素-23水平均明顯降低（P<0.05），且觀察組血清炎癥因子水平明顯低于對照組（P<0.05）。結論 苦碟子注射液聯(lián)合依達拉奉注射液對急性腦梗死患者具有較為滿意的治療效果，可以顯著降低血清炎癥因子，提高患者的日常生活能力，促進神經功能的恢復，且不會增加不良反應。

Objective To investigate the clinical effect of Kudiezi Injection combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (71 cases) with cute cerebral infarction in Yangling Demonstration Zone Hospital from January 2014 to December 2017 were divided into control group (35 cases) and observation group (36 cases) by treatment methods. Patients in the control group were iv administered with Edaravone Injection, 30 mg/time, twice daily. Patients in the observation group were iv administered with Kudiezi Injection on the basis of control group, 40 mL/time, once daily. Patients in two groups were treated for 2 weeks. The clinical effects in two groups were observed, and the levels of ADL scale, NIHSS scale, serum IL-6, TNF-α, and IL-23 before and after treatment between two groups were compared. Results After treatment, the effective rate in the observation group was 91.67%, which was significantly higher than 71.43% in the control group (P<0.05). After treatment, the scores of ADL scale in two groups was increased significantly, but the score of NIHSS scale was significantly decreased (P<0.05), and the ADL scale and NIHSS scale in the observation group was better than those in the control group (P<0.05). After treatment, the levels of IL-6, TNF-α, and IL-23 in two groups were significantly decreased (P<0.05), and the serum inflammatory factors in the observation group was significantly lower than those in the control group (P<0.05). Conclusions Kudiezi Injection combined with Edaravone Injection has a satisfactory therapeutic effect on patients with acute cerebral infarction, which can significantly reduce serum inflammatory factors, improve daily living ability, promote recovery of neurological function, and would not increase adverse reactions.

R971